| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Pathology, 2 Urology, and 3 Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B (NFB) nuclear translocation in human PNI was analyzed using Kaplan-Meier analysis. An increase in proliferation and a decrease in apoptosis were observed in human PNI cells and the PNI model as compared with controls. Three of 15 genes up-regulated in the cDNA microarray were involved in the apoptosis signaling pathway (NFB), and its downstream targets defender against cell death 1 and PIM-2. The increase was corroborated by real-time quantitative PCR and immunofluorescence. NFB nuclear translocation was seen in the in vitro model and human tissues, where strong nuclear expression was associated with a decrease in recurrence-free survival. Addition of genistein and BAY 11-7085 resulted in a decrease in NFB, PIM-2 and defender against cell death 1 as well as a reversal of the inhibition of apoptosis. This is the first description of a biological mechanism and functional significance of PNI. Cancer cells in a perineural location acquire a survival and growth advantage using a NFB survival pathway. Targeting PNI might help detain local spread of the tumor and influence survival. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Prostate cancer currently is the most common noncutaneous malignancy and the second leading cause of cancer death in American men (3) . Mortality in prostate cancer patients is generally attributable to extracapsular spread, which often results in treatment failure and is associated with poor prognosis (4) . Perineural invasion is reported in 85% of prostate cancer patients. More importantly, at least 50% of cases involving extracapsular extension occurred by spread of the cancer within the perineural spaces (5) . Accordingly, current theories suggest that PNI is a key process for extraprostatic spread in prostate cancer.
A previous study with a small number of cases has reported a decrease in apoptotic rate and increased proliferation in cancer cells in a perineural location as compared with cells away from the nerve (6) . However, little is understood about the specific mechanisms that regulate PNI in prostate cancer. We are aware of no new biological studies involving PNI for the last 35 years.
It is likely that a set of key signaling pathways mediate interactions between nerves and cancer cells, which result in PNI and spread of prostate cancer beyond the gland. To address specific mechanisms, we recently developed the PNI in vitro model of PNI (7)
. This model showed that specific interactions existed between prostate cancer cells and nerves, which led to costimulation of growth and PNI in vitro. As we reported previously, DU-145 cells and ganglion neuron neurites migrate toward each other, and the cancer cells contact the nerves and migrate in the perineural sheath (7)
. Accordingly, the PNI in vitro model is useful in permitting the analysis of specific signaling mechanisms that regulate changes in cell proliferation and survival associated with PNI in prostate cancer. To understand mechanisms involved in PNI, we used the PNI in vitro model and human prostate cancer tissue arrays to identify and assess specific factors that might regulate this biology. We report here that prostate cancer cells in a perineural position exhibit a significantly reduced rate of apoptosis and an increased rate of proliferation. Furthermore, we show that up-regulation of nuclear factor B (NFB) and its downstream targets PIM-2 and defender against cell death 1 (DAD-1), all components involved in antiapoptosis signaling cascades, is associated with prostate cancer cells in PNI and most likely regulates the inhibition of apoptosis.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Microchamber System.
DU-145 human prostate carcinoma cells were obtained from American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 supplemented with fetal bovine serum (10%), penicillin (100 units/ml), and streptomycin (100 µg/ml; Sigma, St. Louis, MO). They were maintained at 37°C in a humidified atmosphere of 5% CO2. DU-145 cells were cultured in microchamber culture slides (VWR) as monolayer adherent cells for 11 days to approximately 70–80% confluence. The cultures were then switched to 50% fresh medium and 50% conditioned medium transferred from the PNI coculture model and controls (DU-145 cell growing alone; day 7). Fresh RPMI 1640-based culture medium was also used as a control. Genistein (Sigma) was dissolved in 0.1 mol/L Na2CO3 to make a 10 mmol/L stock solution and added directly to the culture medium at a final concentration of 50 µmol/L. Samples were treated with genistein or vehicle control for 96 hours. All samples were cultured for a total of 10 days and then fixed in 3.7% buffered formaldehyde and processed for in situ apoptotic body labeling.
BAY 11-7085 (Calbiochem, La Jolla, CA) was dissolved in dimethyl sulfoxide to make a 10 mmol/L solution and added directly to the culture medium at a final concentration of 10 µmol/L. Samples were treated with BAY 11-7085 or vehicle control also for 96 hours.
Labeling and Hybridization of cDNA for Microarray Analysis.
Microarray analysis was performed using 30 µg of total RNA. cDNA reverse transcription and fluorescent labeling reactions were carried out using Cy3-labeled nucleotides for control and Cy5-labeled nucleotides for experimental samples. Briefly, cDNA synthesis was initiated by incubating RNA with nonlabeled oligo(dT) primer (1.5 µg; Life Technologies, Inc.) in a 39-µl total volume at 70°C for 10 minutes and chilled on ice. Then, Cy3- and Cy5-labeled dCTPs (Amersham Life Science, Arlington Heights, IL) were added to the appropriate reactions. To each reaction, we added 5x first-strand buffer [12 µl; 250 mmol/L Tris-HCl (pH 8.3), 375 mmol/L KCl, and 15 mmol/L MgCl2), unlabeled nucleotide mix (3 µl; 1 mmol/L dATP, dGTP, and dTTP and 0.1 mmol/L dCTP), 0.1 mol/L dithiothreitol (6 µl), 3 µl of Superscript II reverse transcriptase (200 units/µl), and RNase inhibitor (6 µl; 20 units/µl). After incubation at 42°C for 2 h, cDNA was denatured and neutralized by adding 3 µl of 5 mol/L NaOH and incubation at 37°C for 10 minutes, followed by the addition of 15 µl of Tris-HCl (pH 7.5) and 3 µl of 5 mol/L HCl. The mixture of Cy3 and Cy5 reactions was used as probe and purified using Qiagen PCR purification kit (Qiagen, Valencia, CA). The probe was then mixed with an equal amount of ultrahyb hybridization buffer (Ambion, Austin, TX) and denatured by a 2-minute incubation in boiling water to hybridize in Genomic Systems Hybridization station for 4 hours at 42°C against a microarray chip carrying 6,000 cDNAs obtained from Baylor Microarray Core Facility.4
After hybridization and post-hybridization washes, the slide was scanned immediately in an Axon 4000A dual channel scanner (Axon Instruments, Foster City, CA), and the data were analyzed using the Gene Pix version 3.0 software package (Axon). Genes were considered up- or down-regulated if expression was changed at least 2-fold as compared with the control. Data with low signal intensity, high background, and high variability were eliminated.
First-Strand cDNA Synthesis.
First-strand cDNA were made from total RNA by using RETROscript First Strand Synthesis Kit (Ambion). One microgram of each RNA sample and control template RNA (Ambion) was heated to 75°C for 3 minutes in nuclease-free water containing 2 µl of random decamers. Two microliters of 10x reverse transcription buffer, 4 µl of 10 mmol/L deoxynucleoside triphosphate mix (10 mmol/L each dATP, dCTP, dGTP, and dTTP), 1 µl of placental RNase inhibitor, and 1 µl of Moloney murine leukemia virus reverse transcriptase (100 units/µl) were added to the sample. Each reaction volume was adjusted to 20 µl by adding nuclease-free water. The reaction mixture was incubated at 44°C for 1 hour, followed by incubation at 92°C for 10 minutes to inactivate the reverse transcriptase.
Real-Time Quantitative Polymerase Chain Reaction.
The ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA) was used for quantitative PCR analysis using hypoxanthine phosphoribosyltransferase 1 (HPRT1) as endogenous control. All probes (6-FAM dye labeled at the 5' end and a nonfluorescent quencher at the 3' end of the probe) were combined with primers (Assay-on-Design; Applied Biosystems). Validation experiments were performed using 1:2 diluted templates. The log input amount of RNA versus 
Ct was generated to demonstrate that the efficiencies of the targets and references were approximately equal. DAD-1, NFB, PIM-2 (sequences available on request), and HPRT1 genes were amplified in separate wells in duplicate. Reaction conditions included 10 µl of 2x TaqMan Universal Master Mix (with UNG), 1 µl of HPRT1 or target primers and probes mixture, 100 ng of template cDNA (DU-145 alone, PNI coculture, and PNI coculture with genistein), and nuclease-free water to a 96-well reaction plate. The total reaction volume is 20 µl. The TaqMan cycling conditions were as follows: 2 minutes at 50°C; 10 minutes at 95°C, and 40 cycles of 15 seconds at 95°C followed by 1 minute at 60°C.
Calculation was performed using values of cycle threshold (Ct) as the calibrator from DU-145 cells cultured alone or from DU-145 cells cocultured with DRG. For each experimental sample, the Ct of target, normalized to an endogenous reference and relative to a calibrator, is given by: 2–Ct.
Cohort Enrollment and Tissue Microarrays.
More than 4,000 patients underwent radical prostatectomies at one of the Baylor College of Medicine-affiliated institutions and willingly provided tissues (IRB H-1158). A single pathologist (T. M. W.) performed the pathological analysis of the radical prostatectomies. Of these, 226 were used to build tissue microarrays with the manual tissue arrayer (Beecher Instruments Microarray Technology, Silver Spring, MD). Entry criteria included: (a) no preoperative treatment; (b) surgery between 1983 and 1998; (c) prostate cancer present in the surgical specimen and large enough to be cored (2-mm cores) for microarrays; and (d) PNI present and large enough to be cored. A smaller array using tissues from 50 patients was also built.
Whole mount slides were examined under light microscope, and areas of nerves with PNI were marked. Areas of cancer far away from the nerve were also selected [non-PNI (NPNI)]. One tissue cylinder (2 mm) was punched from the PNI area and the NPNI area of each specimen and transferred to an empty recipient paraffin block. The Baylor Institutional Review Board (IRB H-13024) approved this study.
In situ Labeling of Apoptotic Bodies.
The detection of DNA fragmentation was determined in situ by the terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) technique as described previously (8)
. We used the TACS·XL-diaminobenzidine in situ apoptosis kit (Trevigen Inc., Gaithersburg, MD) following the manufacturer’s indicator with minor modifications and counterstained with methyl green. The TUNEL assay and immunohistochemistry were performed on the tissue microarray slides and paraffin-embedded sections of PNI coculture and controls. A positive control slide prepared by TACS-nuclease and a specimen known to be positive for apoptotic cells were used as positive controls. Substitution of terminal deoxynucleotidyl transferase with distilled water was used as a negative control.
Apoptotic bodies were counted under a light microscope (x400) equipped with an ocular grid (10,000 µm2). The area with highest positive stain was selected for counting. The number of apoptotic bodies was determined in a total of approximately 2,000 prostate cancer cells, normalized to 100 cells, and defined as apoptotic index (AI). At least 10 representative areas without necrosis were selected. Positively stained cells or bodies located in the stroma and lumen were excluded because these apoptotic cells or bodies might have originated from other cell types.
Immunohistochemistry.
The proliferation rate of prostate cancer cells in human tissues and in the PNI in vitro model was determined using the immunoperoxidase method with antibodies against Ki-67 (Santa Cruz Biotechnology, Santa Cruz, CA). Briefly, the slides were deparaffinized and rehydrated in graded ethanol, and antigens were retrieved using steam in 10 mmol/L citrate buffer (pH 6.0) for 30 minutes. The slides were subsequently blocked with blocking protein (DAKO, Carpinteria, CA) for 10 minutes and then incubated with the polyclonal antibody Ki-67 (C-20), for 1 hour at room temperature at a dilution of 1:50. The secondary biotinylated antibody was applied for 30 minutes followed by a 30-minute incubation with streptavidin peroxidase (DAKO LSAB+HRP kit). After rinsing, slides were visualized by diaminobenzidine chromogen solution (DAKO) and counterstained with routine hematoxylin. Positive staining of Ki-67 was confined to the nucleus. The proliferation index (PI) was defined as the ratio of KI-67-positive cancer cells to total cancer cells in the highest positive stain fields (at least 2,000 cells), using a microscopic grid at x400 magnification.
Expression of NFB, PIM-2, and DAD-1 protein in histological sections was analyzed in the smaller tissue array by immunohistochemistry, as described above, with the following antibodies: anti-NFB (Santa Cruz Biotechnology; sc-8008; mouse monoclonal IgG; 1:10 dilution; 30' incubation time); PIM-2 (Santa Cruz Biotechnology; sc-13514; mouse monoclonal IgG; 1:10 dilution; 30' incubation time); and DAD-1 (Santa Cruz Biotechnology; sc-12173; goat polyclonal IgG; 1:10 dilution, 30' incubation time). NFB expression was also analyzed in the large PNI array (226 patients). Cancer cells in PNI or NPNI areas were interpreted for immunoreactivity using a 0 to 3+ quantitative scoring system for both stain intensity and percentage of positive cells (labeling frequency percentage). For intensity, the grading scale ranged from no detectable signal (0) to strong signal seen at low power (3). A designation of 2 was assigned to a moderate signal seen at low to intermediate power, and a designation of 1 was assigned to a weak signal seen only at intermediate to high power.
Nuclear expression of NFB was also quantified in the large PNI tissue microarray using a 0 to 3 scale. Zero correspond to no nuclear staining, 1 is faint nuclear staining, 2 is strong staining observed at medium power in <20% of the cells in the PNI cancer, and 3 is strong staining observed at medium power in >20% of the cells.
Immunofluorescence.
Tissue culture samples were rinsed in Tris-buffered saline followed by a 60-minute incubation with primary antibodies [NFB, 1:50 mouse monoclonal antibody; DAD-1, 1:50 goat polyclonal antibody, (Santa Cruz Biotechnology)]. After a second rinse, the secondary antibodies [fluorescein isothiocyanate-conjugated rabbit antimouse (1:50) and Texas red-conjugated donkey antigoat (1:50), Zymed Laboratories] were added for 30 minutes and rinsed. 4',6-Diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) was used as a counterstain. Observation was performed using a fluorescent inverted Nikon microscope and a Q-capture imaging system.
Statistical Analysis.
Statistical analysis was conducted using Student’s t test for analysis of significant difference between different values and was considered significant at a 95% confidence interval (P < 0.05). The differences in NFB labeling frequencies were compared between PNI cancer and NPNI specimens by using the matched pair Wilcoxon signed-rank test. The correlation of NFB expression with patients’ clinical and pathological variables was analyzed by the Spearman or Pearson correlation test. The predictive value of NFB for recurrence-free survival was determined using the Kaplan-Meier actuarial analysis and the log-rank test. In addition, the Cox proportional hazard regression model was used to analyze the value of using NFB and other pathological and clinical markers to predict the risk of recurrence. The risk ratio and its 95% confidence interval were recorded for each marker. P values of <0.05 were considered statistically significant in all of our analyses. All analyses were performed with statistical software (SPSS 11.0).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The PI in human adenocarcinoma cells at PNI sites had a mean value of 10.25 ± 1.2, whereas the PI in NPNI sites had a mean value of 8.16 ± 0.98 (P = 0.034). The AI in cancer cells at sites of PNI was significantly lower as compared with AI in prostate cancer cells not associated with PNI. The mean AI at PNI sites was 0.68 ± 0.16 as compared with a mean AI of 1.8 ± 0.42 at sites of cancer with no PNI (P = 0.010; Fig. 2
).
|
|
).
Overexpression of Genes Related to Proliferation and Apoptosis in Prostate cancer in Perineural Location.
Profiling of genes differentially expressed in DU-145/DRG cocultures relative to DU-145 controls by gene microarray analysis showed overexpression (of at least a 3-fold differential) of 15 genes. Of these, three were known components of antiapoptosis signaling pathways. These included NFB and its downstream targets PIM-2 and DAD-1. Overexpression of these factors in perineural cancer cells relative to cancer cells not associated with nerves was confirmed by quantitative PCR and showed that NFB, DAD-1, and PIM-2 were each overexpressed 1.9-, 1.6-, and 2.02-fold, respectively, in DU-145/DRG cocultures as compared with DU-145 cells growing alone (Fig. 3)
.
|
B is predominantly cytoplasmic in the DU-145 cells cultured without the nerve (control), whereas an overall increase in staining intensity and increased nuclear localization (nuclear translocation) was observed in DU-145 cells cocultured with DRG nerves in the PNI model (Fig. 4)
. In addition, overexpression of DAD-1 protein was evident in DU-145/DRG cocultures as compared with DU-145 controls (Fig. 4)
, and DAD-1 exhibited colocalization with NFB in the nucleus. Immunohistochemistry for NFB, DAD-1, and PIM-2 on paraffin-embedded tissues of the PNI coculture samples confirmed the quantitative PCR and immunofluorescence results (data not shown).
|
Reversal of Perineural Invasion Antiapoptotic Effect by Genistein and BAY 11-7085.
DU-145 cells exposed to 50% (v/v) of conditioned medium derived from DU-145/DRG cocultures also showed a decrease in the AI relative to vehicle controls. There was a decrease in the mean AI in the cells cultured with PNI coculture-conditioned medium (AI = 11.02; n = 8) compared with cells cultured with control DU-145-conditioned medium (AI = 13.52; n = 8; P < 0.000; Fig. 2C
). The AI index showed a significant increase with the addition of genistein (AI = 17.32; P < 0.000; n = 16). The addition of genistein also lowered the levels of its effector targets, NFB (0.62x), PIM-2 (0.57x), and DAD-1 (0.77x; Fig. 3
). The decrease at the RNA level was translated into a decrease in protein expression as demonstrated by immunofluorescence (data not shown).
The addition of the inhibitor of IB phosphorylation, BAY 11-7085, demonstrated similar results. In contrast to controls (DU-145 cocultured with nerves), nuclear translocation of NFB was not identified by immunofluorescence of the PNI in vitro model treated with BAY 11-7085 (Fig. 5)
. Quantitative PCR showed a decrease in NFB and its downstream effectors DAD-1 and PIM-2. NFB RNA levels in BAY 11-7085-treated cells were 0.60 those of control. Similarly, DAD-1 RNA levels in BAY 11-7085-treated cells were 0.85 those of control. We also identified a decrease in PIM-2 in BAY 11-7085-treated cells (0.48) as compared with controls (Fig. 3)
. More significantly, the apoptotic ratio increases in BAY 11-7085-treated cells, indicating a functional response to the IB phosphorylation inhibition. The mean AI increase in cells treated with BAY 11-7085 was 125.5 ± 5.44 (n = 4) as compared with control DU-145-conditioned medium (AI = 104.25 ± 10.14; n = 3; P = 0.0164; Fig. 5
).
|
B in Human Perineural Invasion.B levels were higher in the cells in PNI than in those located away from the nerve (index, 7.18 ± 2.39 versus 2.34 ± 2.5; P = 0.000; Fig. 6B
). Cytoplasmic expression of NFB was present in all cells in PNI. Nuclear expression was identified in 72.6% of the patients (98 of 135); however, strong nuclear expression (grades 2 and 3) was present in only 38.5% and 8.1% of the patients, respectively (Fig. 6A)
. Strong nuclear NFB expression in PNI correlated with other clinicopathological parameters including extracapsular extension (r2 = 0.213; P = 0.131) and Gleason score (r2 = 0.235; P = 0.006).
|
B expression, defined as grade 2 and 3, were associated with a decrease biochemical-free survival. There was a significant difference in recurrence-free survival between cases with no expression or low expression of nuclear NFB in the PNI (mean survival, 78.62 months) and those with strong expression [median survival, 67.52 months; hazard ratio = 2.053 (1.123–3.755); P = 0.0195; Fig. 6C
]. This difference was significant on univariate analysis but not on multivariate analysis. |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B and its downstream effectors DAD-1 and PIM-2 was elevated in perineural cancer cells. The addition of genistein or BAY 11-7085 reversed alterations in apoptosis and lowered RNA levels of NFB, PIM-2, and DAD-1, suggesting that the NFB signaling pathway regulates the alterations observed in PNI. Furthermore, nuclear translocation of NFB was associated with decreased biochemical recurrence-free survival, corroborating the significance of the phenomenon in human tissues. Neurons have numerous interactions with the epithelial and stromal components of the prostate gland. They are involved in prostate development and maintenance of histological architecture and function in the adult gland (9, 10, 11, 12, 13, 14) . However, the most common interaction between nerves and prostate epithelium during tumorigenesis is PNI. The biological and clinical significance of PNI in prostate cancer has been the subject of intense debate (15, 16, 17, 18) . Numerous other authors have reported varying degrees of clinical prognostic significance for PNI (15 , 17 , 19, 20, 21, 22, 23) . A significant study demonstrated that the volume of tumor around the nerve, labeled as the PNI diameter, was an independent predictor of survival (24) . The greater the PNI diameter, the stronger the risk of recurrence for the patient becomes. These data suggest that that not all PNIs are equal and that proximity to the nerve might provide greater growth and survival advantages in various degrees.
These studies, taken together, suggest that cancer cells in the perineural environment are influenced by the nerve to evolve a growth and survival advantage, the manifestation of which is increased tumor volume around the nerve. It follows that cancers that exploit the advantages found in the perineural microenvironment would be predicted to have a more aggressive biology and therefore the worst survival. These findings show the critical importance of studying the cancer microenvironment, including the neuroenvironment, as a key regulatory component of cancer progression. It seems likely that cancer cells have different biological abilities according to the elements that surround them. It is possible that the perineural space creates an environment that not only provides an avenue for prostate cancer invasion and spread but also creates the conditions for heightened aggressiveness that has been shown to be associated with PNI in prostate cancer. Data presented here support this hypothesis and suggest that the NFB pathway is key in mediating this biology.
NFB is a known regulatory element in a major survival pathway. In the present study, we demonstrate that NFB is up-regulated in the PNI in vitro model at the RNA and protein levels. The data also strongly suggest that NFB is translocated to the nuclei in prostate cancer cells in a perineural location. This process occurs in the in vitro PNI model as well as in human tissues. The latter is corroborated by the fact that strong nuclear NFB expression in human perineural cells is associated with decreased biochemical recurrence-free survival. The lack of multivariate significance could be due to a number of factors such as a small population and the relatively strong correlation between nuclear NFB and extracapsular extension and Gleason score. More importantly, this finding is a clear demonstration that nuclear expression/translocation is clearly related to a more aggressive phenotype of prostate cancer and is a clear demonstration of the biological significance of nuclear translocation of NFB in the perineural space.
PIM-2 and DAD-1 are downstream targets in the NFB survival pathway (25)
. Both have been associated with antiapoptotic functions. Data presented here show up-regulation of these genes. Functional studies with genistein, a known inhibitor of constitutive and inducible NFB activation (26
, 27)
, and BAY 11-7085, a specific inhibitor of IB phosphorylation (28)
, suggest that the NFB and its downstream effectors are likely to be a key regulatory component in PNI. Both genistein and BAY 11-7085 seem to inhibit the up-regulation of NFB as well as PIM-2 and DAD-1. Nuclear translocation seems to be inhibited and is best noted with BAY 11-7085, as would be expected with a molecule that inhibits phosphorylation of IB. More importantly, the functional consequence of the activation of the NFB pathway in the perineural space, inhibition of apoptosis, is partially reversed with both compounds. Accordingly, targeting the NFB pathway may be a novel therapeutic approach to limit metastatic spread via PNI.
The upstream regulatory pathways that affect NFB in PNI are currently unknown. Whereas neural cell adhesion molecule (NCAM) has been described in numerous cancers (29, 30, 31)
, we have not been able to identify NCAM in prostate cancer cells. However, nerves with prostate cancer PNI have higher levels of NCAM as compared with nerves without PNI (32)
. The NCAM promoter is known to be activated by neural injury, such as cancer invading the nerve. Krushel (33)
demonstrated that NFB-mediated transcription was increased after NCAM binding to astrocytes and neurons. NCAM homophilic binding at the cell membrane leads to increased NFB binding to DNA and transcriptional activation in both neurons and astrocytes. Because NCAM and NFB are present in the post-synaptic density, it is possible that higher levels of NCAM in the nerve might increase NFB levels in the prostate cancer cells as they contact the nerve in PNI. This represents a potential route allowing direct communication between the cancer cells and the nerves. The relationship between NFB and NCAM is bidirectional because nitric oxide also stimulates protein binding to a NFB site in the promoter of the NCAM gene (34)
. Other potential upstream regulators are neuropeptides, which are known to be present in prostate nerves. Both bombesin (35)
and dopamine (36)
have been shown to stimulate NFB activation.
Our studies showed that PNI is an interactive process between the cancer cells and nerves (7) . In the present study, we demonstrate that this interaction likely results in growth and survival advantages for the prostate cancer cells in the perineural location and provides a putative mechanism for this phenomenon. We believe that this is the first description of a biological mechanism and functional significance associated with PNI. A more clear understanding of the specific biological mechanisms involved in PNI and the inhibition of cancer cell apoptosis may lead to improved diagnostics/prognostics and to the development of new therapeutic strategies.
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Gustavo E. Ayala, Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Phone: 713-394-6487; Fax: 713-793-1603; E-mail: gayala{at}bcm.tmc.edu
4 http://www.bcm.tmc.edu/microarray. 
Received 3/ 8/04. Revised 6/24/04. Accepted 7/ 9/04.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. Kadoch, E. B. Dinca, R. Voicu, L. Chen, D. Nguyen, S. Parikh, J. Karrim, M. A. Shuman, C. A. Lowell, P. A. Treseler, et al. Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model Clin. Cancer Res., March 15, 2009; 15(6): 1989 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Sorensen, P. J. Wild, A. Mortezavi, K. Adolf, N. Torring, S. Heeboll, B. P. Ulhoi, P. Ottosen, T. Sulser, T. Hermanns, et al. Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy Clin. Cancer Res., February 15, 2009; 15(4): 1400 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cai, J. Wang, R. Li, G. Ayala, M. Ittmann, and M. Liu GGAP2/PIKE-A Directly Activates Both the Akt and Nuclear Factor-{kappa}B Pathways and Promotes Prostate Cancer Progression Cancer Res., February 1, 2009; 69(3): 819 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Ayala, H. Dai, M. Powell, R. Li, Y. Ding, T. M. Wheeler, D. Shine, D. Kadmon, T. Thompson, B. J. Miles, et al. Cancer-Related Axonogenesis and Neurogenesis in Prostate Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7593 - 7603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ayala, J. Yan, R. Li, Y. Ding, T. C. Thompson, M. P. Mims, T. G. Hayes, V. MacDonnell, R. G. Lynch, A. Frolov, et al. Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt Clin. Cancer Res., November 15, 2008; 14(22): 7511 - 7518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xie, D. W. Wolff, M.-F. Lin, and Y. Tu Vasoactive Intestinal Peptide Transactivates the Androgen Receptor through a Protein Kinase A-Dependent Extracellular Signal-Regulated Kinase Pathway in Prostate Cancer LNCaP Cells Mol. Pharmacol., July 1, 2007; 72(1): 73 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Peant, J.-S. Diallo, L. Lessard, N. Delvoye, C. Le Page, F. Saad, and A.-M. Mes-Masson Regulation of I{kappa}B Kinase {varepsilon} Expression by the Androgen Receptor and the Nuclear Factor-{kappa}B Transcription Factor in Prostate Cancer Mol. Cancer Res., January 1, 2007; 5(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lessard, P. I. Karakiewicz, P. Bellon-Gagnon, M. Alam-Fahmy, H. A. Ismail, A.-M. Mes-Masson, and F. Saad Nuclear Localization of Nuclear Factor-{kappa}B p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases. Clin. Cancer Res., October 1, 2006; 12(19): 5741 - 5745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. True, I. Coleman, S. Hawley, C.-Y. Huang, D. Gifford, R. Coleman, T. M. Beer, E. Gelmann, M. Datta, E. Mostaghel, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma PNAS, July 18, 2006; 103(29): 10991 - 10996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Ayala, H. Dai, S. A. Tahir, R. Li, T. Timme, M. Ittmann, A. Frolov, T. M. Wheeler, D. Rowley, and T. C. Thompson Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res., May 15, 2006; 66(10): 5159 - 5164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koide, T. Yamada, R. Shibata, T. Mori, M. Fukuma, K. Yamazaki, K. Aiura, M. Shimazu, S. Hirohashi, Y. Nimura, et al. Establishment of Perineural Invasion Models and Analysis of Gene Expression Revealed an Invariant Chain (CD74) as a Possible Molecule Involved in Perineural Invasion in Pancreatic Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2419 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hermani, J. Hess, B. De Servi, S. Medunjanin, R. Grobholz, L. Trojan, P. Angel, and D. Mayer Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5146 - 5152. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
